ArticleClinical drug investigation2026
Population Pharmacokinetics of Amlodipine and Telmisartan Following Oral Administration of a Single-Pill Fixed-Dose Combination in Healthy Korean Male Subjects.
Article in Clinical drug investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND AND
objectiveFixed-dose combinations (FDCs) of amlodipine and telmisartan are widely used for hypertension management owing to their efficacy and improved adherence. This study aimed to characterize the pharmacokinetics (PKs) of both drugs after a single oral dose of a single-pill FDC of amlodipine 5 mg/telmisartan 80 mg in healthy Korean males.
methodsA total of 681 amlodipine and 1500 telmisartan plasma concentrations from 32 healthy Korean males were retrospectively obtained from a bioequivalence study. Noncompartmental analysis and population analysis were conducted using WinNonLin™ (Pharsight Corp., Mountain View, CA, USA) and NONMEM
resultsAmlodipine exhibited a longer half-life and a larger apparent volume of distribution than telmisartan. Telmisartan PKs showed high interindividual (45.9% for absorption rate constant, 45.3% for apparent volume of distribution of the central compartment [V
conclusionsTo our knowledge, this is the first population PK study to characterize the PKs of amlodipine and telmisartan co-administered as a single-pill FDC and to identify preliminary covariates that may influence their PK profiles.
Indexed as
Identifiers
41436901What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.